title: Sentinel lymph node mapping for primary breast cancer.
abstract: The tumor status of the axillary lymph nodes is the single most important predictor of survival for patients with primary breast cancer. Because of its essential role in staging, regional control, and perhaps survival, axillary lymph node dissection (ALND) has long been the standard of care for patients with operable breast cancer. During the past decade, the introduction and development of sentinel lymph node dissection (SLND) for primary breast cancer have allowed surgeons to determine the tumor status of the axilla without a standard level I and II ALND. Several well-designed studies have documented that SLND is an effective way of assessing axillary nodal status with minimal morbidity and high accuracy. We address the current status and future directions of SLND for primary breast cancer.
authors.affiliation: Joyce Eisenberg Keefer Breast Center, John Wayne Cancer Institute at St. John's Health Center, 2200 Santa Monica Boulevard, Santa Monica, CA 90404, USA.
authors.forename: Lori L
authors.initials: LL
authors.lastname: Wilson
authors.forename: Armando E
authors.initials: AE
authors.lastname: Giuliano
mesh_terms: D001365:Axilla / Q000473:pathology; D001943:Breast Neoplasms / Q000175:diagnosis* / Q000473:pathology*; D002986:Clinical Trials as Topic; D005060:Europe; D005260:Female; D006801:Humans; D008198:Lymph Nodes / Q000473:pathology; D008495:Medical Oncology / Q000379:methods; D009367:Neoplasm Staging / Q000379:methods*; D015203:Reproducibility of Results; D021701:Sentinel Lymph Node Biopsy / Q000379:methods*; D014481:United States